CORT ALERT: Ongoing Investigation Into Corcept Therapeutics Incorporated - Contact Levi & Korsinsky

Core Viewpoint - Corcept Therapeutics Incorporated is under investigation for potential violations of federal securities laws following the FDA's denial of approval for its new drug application for relacorilant, leading to a significant drop in its stock price [1][2][3]. Group 1: Company Developments - On December 31, 2025, Corcept announced it received a Complete Response Letter (CRL) from the FDA, denying approval for relacorilant as a treatment for hypertension secondary to hypercortisolism [2]. - The FDA acknowledged previous trial results but required additional evidence of effectiveness for a favorable benefit-risk assessment [2]. Group 2: Market Reaction - Following the FDA's announcement, Corcept's stock price fell by $31.42, a decrease of 44.76%, opening at $38.78 per share, marking a new 52-week low [3]. - This stock price drop reflects levels not seen since September 2024, indicating a significant market reaction to the FDA's decision [3].